A groundbreaking clinical trial, STRIVE, has arrived in Aotearoa New Zealand, offering a glimmer of hope for those affected by vulvar cancer. This trial aims to revolutionize the way we approach this disease, and it's a development that deserves our attention.
The Battle Against Vulvar Cancer: A New Front Opens
The Australian New Zealand Gynaecological Oncology Group (ANZGOG) has joined forces with the Canadian Cancer Trials Group (CCTG) to bring the STRIVE trial to our shores. But here's where it gets controversial: vulvar cancer, a rare and often misunderstood disease, presents unique challenges due to its diverse origins.
Understanding the Enemy: HPV vs. Lichensclerosus
Vulvar squamous cell carcinoma (VSCC), the most common form of vulvar cancer, arises through two distinct pathways. HPV-associated VSCC and HPV-independent VSCC, often linked to lichensclerosus, an autoimmune condition. The symptoms are clear: persistent itching, bleeding, and ulcerated lesions, typically on the labia.
The STRIVE Trial: A Global Effort for Personalized Care
STRIVE is an international, prospective study designed to refine surgical decisions for VSCC patients based on tumor biology. Led by Professor Paul Cohen and Dr. Lois Eva, this trial aims to estimate 3-year local recurrence rates and guide surgical management.
Recent evidence suggests that HPV-independent VSCC, arising from lichensclerosus, may require a different treatment approach. If certain conditions, like abnormalities in the p53 gene and pre-cancerous changes (dVIN), are present at the edge of the removed tissue, it could lead to more cancer recurrences.
A Personalized Approach: Less Aggressive, More Effective
The STRIVE study hopes to answer these complex questions. Early-stage HPV-associated VSCC may not need further treatment after initial surgery, potentially reducing side effects and the risk of cancer recurrence. Conversely, HPV-independent VSCC may benefit from more extensive surgery based on tumor tissue assessment.
Closing the Knowledge Gap: International Collaboration
Given the rarity of vulvar cancer, international collaboration is vital. The STRIVE trial brings together global experts to enhance clinical evidence and improve outcomes for women affected by this disease.
For more information, visit https://youtu.be/xZdSn0JPwWY or www.anzgog.org.au.
Eligibility criteria for the trial include adult women diagnosed with primary vulvar squamous cell carcinoma (VSCC) FIGO stage I-II disease.
The first Australasian site at Auckland City Hospital officially opened on January 30, 2026, and is actively recruiting participants.
A Step Towards Better Outcomes
Data from STRIVE will fill critical gaps in our understanding of VSCC recurrence. By evaluating outcomes based on HPV status and molecular markers, the study aims to improve risk stratification, reduce local recurrence rates, and strengthen clinical guidelines.
This trial represents a significant step forward in the surgical management of VSCC, offering a more personalized and effective approach.
Final Thoughts: A Call for Discussion
The STRIVE trial raises important questions about the best way to treat vulvar cancer. As we move forward, it's crucial to consider the potential benefits of less aggressive treatment for HPV-associated cancers and the role of personalized care.
What are your thoughts on this groundbreaking trial? Do you think it will lead to better outcomes for vulvar cancer patients? We'd love to hear your opinions in the comments below!
